Vishwa-Syntharo Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 23-10-2024
- Paid Up Capital ₹ 5.00 M
as on 23-10-2024
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.26 Cr
as on 23-10-2024
- Revenue 79.83%
(FY 2023)
- Profit 343.87%
(FY 2023)
- Ebitda 4461.97%
(FY 2023)
- Net Worth 298.94%
(FY 2023)
- Total Assets 20.43%
(FY 2023)
About Vishwa-Syntharo Pharmachem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company has closed loans amounting to ₹3.26 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sankara Rajaram, Lars Muller, and Sita Iyer serve as directors at the Company.
- CIN/LLPIN
U24200TN2015PTC102904
- Company No.
102904
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 2015
- Date of AGM
21 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Vishwa-Syntharo Pharmachem Private Limited offer?
Vishwa-Syntharo Pharmachem Private Limited offers a wide range of products and services, including Research and Development (R&D) Work, Product Development Research.
Who are the key members and board of directors at Vishwa-Syntharo Pharmachem?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sankara Rajaram  | Director | 05-Nov-2015 | Current |
Lars Muller  | Director | 05-Nov-2015 | Current |
| Sita Iyer | Alternate Director | 10-Dec-2015 | Current |
Financial Performance of Vishwa-Syntharo Pharmachem.
Vishwa-Syntharo Pharmachem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 79.83% increase. The company also saw a substantial improvement in profitability, with a 343.87% increase in profit. The company's net worth Soared by an impressive increase of 298.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vishwa-Syntharo Pharmachem?
In 2023, Vishwa-Syntharo Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 29 Jul 2022 | ₹3.26 Cr | Satisfied |
How Many Employees Work at Vishwa-Syntharo Pharmachem?
Vishwa-Syntharo Pharmachem has a workforce of 36 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vishwa-Syntharo Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vishwa-Syntharo Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
